These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37309248)

  • 1. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
    Takeda K; Yamaguchi Y; Taguri M; Morita S
    Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
    Takeda K; Morita S; Taguri M
    Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A generalized Bayesian optimal interval design for dose optimization in immunotherapy.
    Xia Q; Takeda K; Yamaguchi Y; Zhang J
    Pharm Stat; 2024; 23(4):480-494. PubMed ID: 38295856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations.
    Kakizume T; Takeda K; Taguri M; Morita S
    Stat Methods Med Res; 2024 Apr; 33(4):716-727. PubMed ID: 38444354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
    Takeda K; Taguri M; Morita S
    Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
    Takeda K; Zhu J; Li R; Yamaguchi Y
    Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.
    Mu R; Hu Z; Xu G; Pan H
    BMC Med Res Methodol; 2021 Dec; 21(1):278. PubMed ID: 34895153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
    Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
    Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
    Li R; Takeda K; Rong A
    Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
    McGovern A; Chapple AG; Ma C
    Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects.
    Yin Z; Mander AP; de Bono JS; Zheng H; Yap C
    JCO Precis Oncol; 2024 Jan; 8():e2300441. PubMed ID: 38181316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
    Andrillon A; Chevret S; Lee SM; Biard L
    Stat Med; 2022 Dec; 41(29):5753-5766. PubMed ID: 36259523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-to-event calibration-free odds design: A robust efficient design for phase I trials with late-onset outcomes.
    Jin H; Yin G
    Pharm Stat; 2023; 22(5):773-783. PubMed ID: 37095681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
    van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
    BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
    Zhao Y; Liu R; Takeda K
    Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.